About this trial
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is;
1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen.
Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.
Eligibility criteria
Qualifiers
No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms
Negative serological testing for specific IgE to pollens, house dust mite and insect venoms
Patients aged 18 years or older
Participants over the age of 18 years
Disqualifiers
Patients under the age of 18 years
Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom
Participants who are pregnant
Participants who cannot adequately understand verbal and / or written explanations given in English
Trial design
Treatments tested in this trial
- Venepuncture
- Allergen Specific Immunotherapy
- Allergen Specific Immunotherapy
Treatment groups
Sponsors and collaborators
Hull University Teaching Hospitals NHS Trust
Lead sponsor
Health Education England, Wessex
Collaborator
University of Manchester
Collaborator